Diabetes

Natural product-based combinatorial therapy for TIIDM, Metabolic defects and Longevity: A therapeutic mix encompassing Nordihydroguaiaretic acid (NDGA) & Mangosteen  (NDGAM) increases Sirtuin-4 expression, augments insulin secretion, reduces metabolic stress, improves glucose uptake, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 04/October/2017, 1.53 am
Natural product-based combinatorial therapy for TIIDM, Metabolic defects and Longevity: A therapeutic mix encompassing Nordihydroguaiaretic acid (NDGA) & Mangosteen  (NDGAM) increases Sirtuin-4 expression, augments insulin secretion, reduces metabolic stress, improves glucose uptake, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 04/October/2017, 1.53 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the “Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, NC 27701, USA; Department of…

read more

Natural product-derived regenerative therapy for reversing diabetes: a therapeutic mix encompassing Berberine, Leucine, and Genistein (BLG) increases the expression of Sox17, Sox2, Pdx-1, and Ngn3, decreases mTOR expression, promotes regeneration of insulin-producing ß cells, increases insulin secretion, promotes glucose homeostasis and reverses T1D and T2D via down regulation of its target gene, 2/October/2017, 12.14 am
Natural product-derived regenerative therapy for reversing diabetes: a therapeutic mix encompassing Berberine, Leucine, and Genistein (BLG) increases the expression of Sox17, Sox2, Pdx-1, and Ngn3, decreases mTOR expression, promotes regeneration of insulin-producing ß cells, increases insulin secretion, promotes glucose homeostasis and reverses T1D and T2D via down regulation of its target gene, 2/October/2017, 12.14 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Longevity Institute, School of Gerontology, Department of Biological Sciences, University of Southern California, 3715 McClintock Avenue, Los Angeles, California, USA; and Koch Institute…

read more

Antidepressant-based therapy for Metabolic diseases: Fluoxetine, an anti-depressant drug, increases the expression of Caveolin-1, stabilizes insulin receptor, promotes insulin sensitivity, incrases vasorelaxation, and decreases the risk of hyperglycemia and TIIDM via up regulation of its target gene.., 1/October/2017, 11.51 pm
Antidepressant-based therapy for Metabolic diseases: Fluoxetine, an anti-depressant drug, increases the expression of Caveolin-1, stabilizes insulin receptor, promotes insulin sensitivity, incrases vasorelaxation, and decreases the risk of hyperglycemia and TIIDM via up regulation of its target gene.., 1/October/2017, 11.51 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland shows that “MicroRNAs 103 and 107 regulate insulin sensitivity.” This study was published in the June 8, 2011 Nature [One of…

read more

Natural product-based therapy for TIIDM and obesity-associated metabolic deficits: Folic acid, isolated from Lentils, among others, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 1/October/2017, 11.43 pm
Natural product-based therapy for TIIDM and obesity-associated metabolic deficits: Folic acid, isolated from Lentils, among others, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 1/October/2017, 11.43 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite…

read more

Natural product-based therapy for TIIDM: A pharmaceutical mixture encompassing Fucoidan, Icariin, Piceatannol, Polydatin , α-lipoic acid (FIPPL) augments the expression of FGF19 and FGF1,   attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIIDM via up regulation of its target gene, 30/September/2017, 12.09 am
Natural product-based therapy for TIIDM: A pharmaceutical mixture encompassing Fucoidan, Icariin, Piceatannol, Polydatin , α-lipoic acid (FIPPL) augments the expression of FGF19 and FGF1,   attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIIDM via up regulation of its target gene, 30/September/2017, 12.09 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection of FGF1 induces sustained…

read more

Molecular therapy for TIIDM and obesity-associated metabolic deficits: Duloxetine (Trade name: Cymbalta), an anti-anxiety drug,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 28/September/2017, 5.30 am
Molecular therapy for TIIDM and obesity-associated metabolic deficits: Duloxetine (Trade name: Cymbalta), an anti-anxiety drug,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 28/September/2017, 5.30 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite…

read more
Start Typing